Drug
Lumacaftor clinical trials
Also written VX-809.
Keep track of what changes. Save the lumacaftor studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
20 studies that test it; most in 2013 (4)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2010 | 2 |
| 2013 | 4 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 1
Vertex Pharmaceuticals Incorporated (17) · Istituto Auxologico Italiano (1) · Qanatpharma Canada LTD (1) · Qanatpharma AG (1)
Often tested with
Tested in the same studies.
Ivacaftor (16) · Lumacaftor, ivacaftor drug combination (1) · Ciprofloxacin (1) · Itraconazole (1) · Rifampin (1)
Studies
Open first, then newest update. How each study uses lumacaftor is read from its arms, and is right about nine times in ten.
Testing it · 20
- Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure PatientsRecruitingPhase 2Qanatpharma AGNCT07695090Written as Lumacaftor 200 MG
- Mutation-specific Therapy for the Long QT SyndromeCompletedPhase 2Istituto Auxologico ItalianoNCT04581408Written as Lumacaftor / Ivacaftor, Orkambi® Oral Tablet
- Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment InitiationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04235140Written as LUM/IVA
- Bioequivalence and Food Effect Bioavailability Study of Lumacaftor Film-Coated TabletsCompletedPhase 1Qanatpharma Canada LTDNCT05968612Written as Lumacaftor 200 mg/Ivacaftor 125 mg Film-Coated Tablet
- Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508delCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03601637Written as LUM
- A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508delCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT03625466Written as LUM/IVA
- Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With IvacaftorCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT02544451Written as LUM/IVA
- A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03125395Written as LUM/IVA
- A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR MutationCompletedPhase 4Vertex Pharmaceuticals IncorporatedNCT02875366Written as LUM/IVA
- Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR MutationCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT03061331Written as LUM/IVA
- Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung DiseaseCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT02390219Written as Lumacaftor
- A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT02514473Written as VX-809
- Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT01897233Written as Lumacaftor
- Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR MutationCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT01225211Written as Lumacaftor
- Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene MutationCompletedPhase 2Vertex Pharmaceuticals IncorporatedNCT00865904Written as VX-809
- A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With IvacaftorCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT01899105Written as lumacaftor
- Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy SubjectsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT01888393Written as lumacaftor 200 mg q12h + ivacaftor 250 mg q12h
- A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult SubjectsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT01768663Written as Lumacaftor
- Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy SubjectsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT01216046Written as VX-809
- Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy SubjectsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT00966602Written as VX-809
Given in every arm · 2 — lumacaftor is usual care beside what is tested
- A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR MutationTerminatedPhase 4Vertex Pharmaceuticals IncorporatedNCT02823470Written as LUM/IVA
- Phase 1, QT/QTC Interval Study in Healthy SubjectsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT01910415Written as Lumacaftor
Codes
What other systems call lumacaftor · ClinicalTrials.gg INT005963
- MeSH (NLM) C569105lumacaftorOne source NLM
- UNII (FDA) EGP8L81APKLUMACAFTORConfirmed FDA, NLM, Wikidata
- RxNorm 1655922Confirmed FDA, Wikidata
- Wikidata Q6703005lumacaftorConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170136LumacaftorOne source FDA
- DrugBank DB09280One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C569105 | lumacaftor | One source NLM |
| UNII (FDA) | EGP8L81APK | LUMACAFTOR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1655922 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6703005 | lumacaftor | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170136 | Lumacaftor | One source FDA |
| DrugBank | DB09280 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.